{
    "nctId": "NCT02659501",
    "briefTitle": "Liposomal Bupivacaine in Implant Based Breast Reconstruction",
    "officialTitle": "Liposomal Bupivacaine in Implant Based Breast Reconstruction",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Postoperative Pain",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 24,
    "primaryOutcomeMeasure": "The Effect of Liposomal Bupivacaine on Average Postoperative Pain Levels on Postoperative Day 1.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women undergoing immediate unilateral or bilateral tissue-expander breast reconstruction following skin-sparing or nipple-sparing mastectomy\n\nExclusion Criteria:\n\n* Women who are unable to give informed consent to participate in this study\n* Women with a documented history of hypersensitivity reactions to local-anesthetic agents\n* Women with a diagnosis of chronic pain disorders such as fibromyalgia, chronic migraine headaches, or psychiatric disorders other than depression or anxiety\n* Women who are currently pregnant\n* Women undergoing tissue expander based breast reconstruction with a muscle flap in combination with a tissue expander\n* Women with impaired hepatic function",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}